



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Refine Search

Search Results -

| Term | Documents |
|---|-----------|
| HSV | 11309 |
| HSVS | 52 |
| MUTANT | 51687 |
| MUTANTS | 35380 |
| (11 AND (HSV ADJ MUTANT)).PGPB,USPT,EPAB,JPAB,DWPI,TDBD. | 2 |
| (L11 AND (HSV ADJ MUTANT)).PGPB,USPT,EPAB,JPAB,DWPI,TDBD. | 2 |

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L12

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Monday, December 29, 2003 [Printable Copy](#) [Create Case](#)

Set Name **Query**
 side by side

Hit Count

**Set
Name**
 result set

DB=PGPB,USPT,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=AND

| | | | |
|------------|--|----|------------|
| <u>L12</u> | L11 and (HSV adj mutant) | 2 | <u>L12</u> |
| <u>L11</u> | L9 and (cancer or melanoma or tumor or tumour) | 25 | <u>L11</u> |
| <u>L10</u> | L9 and (HSV adj 1716) | 0 | <u>L10</u> |
| <u>L9</u> | Roizman-bernard.in. | 49 | <u>L9</u> |
| <u>L8</u> | Rozman-bernard.in. | 0 | <u>L8</u> |
| <u>L7</u> | L6 and (HSV adj 1716) | 0 | <u>L7</u> |

| | | | |
|-----------|---|----|-----------|
| <u>L6</u> | Martuza-robert-L\$.in. | 19 | <u>L6</u> |
| <u>L5</u> | (HSV adj 1716) and (cancer or tumor or tumour) | 2 | <u>L5</u> |
| <u>L4</u> | L2 and (HSV adj 1716) | 0 | <u>L4</u> |
| <u>L3</u> | L2 same (HSV adj 1716) | 0 | <u>L3</u> |
| <u>L2</u> | (HSV adj mutant) same (cancer or tumor or tumour) | 17 | <u>L2</u> |
| <u>L1</u> | Brown-susanne-M\$.in. | 13 | <u>L1</u> |

END OF SEARCH HISTORY

localized intraperitoneal malignancy. Human malignant mesothelioma cells supported the growth of *HSV*-1716* and were rapidly lysed in vitro. Intraperitoneal injection of *HSV*-1716* into animals with established mesothelioma *tumor* nodules reduced *tumor* burden and significantly prolonged survival in an animal model of non-CNS localized human malignancy. Importantly, the *HSV*-1716* mutant was 'replication-restricted' to malignant cells, in that it did not disseminate or persist after intraperitoneal injection into SCID mice bearing human tumors. These...

... replication-restricted HSV mutant 1716 may be efficacious and safe for use in localized human malignancies of non-neuronal origin such as malignant mesothelioma, brain *cancer*, ovarian carcinoma, or bladder *cancer*.

?ds

| Set | Items | Description |
|-----|-------|--|
| S1 | 29 | (HSV (W) 1716) (S) (CANCER OR MELANOMA OR TUMOR OR TUMOUR - OR NEOPLASTIC) |
| S2 | 10 | RD (unique items) |
| S3 | 31 | (HSV (W) 1716) AND (CANCER OR NEOPLASTIC OR TUMOR OR TUMOUR - R) |
| S4 | 1 | S3 NOT PY>1996 |

?logoff

```

29dec03 12:08:44 User259876 Session D579.2
$1.32      0.413 DialUnits File155
$1.47      7 Type(s) in Format 3
$1.47      .7 Types
$2.79 Estimated cost File155
$0.54      0.182 DialUnits File159
$0.78      3 Type(s) in Format 3
$0.78      3 Types
$1.32 Estimated cost File159
$2.67      0.476 DialUnits File5
$1.75      1 Type(s) in Format 3
$1.75      1 Types
$4.42 Estimated cost File5
$2.66      0.288 DialUnits File73
$2.66 Estimated cost File73
OneSearch, 4 files, 1.360 DialUnits FileOS
$1.62 TELNET
$12.81 Estimated cost this search
$13.16 Estimated total session cost 1.447 DialUnits

```

Status: Signed Off. (7 minutes)

Status: Path 1 of [Dialog Information Services via Modem]

Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog)
Trying 31060000009999...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

***** HHHHHHHH SSSSSSSS?

Status: Signing onto Dialog

ENTER PASSWORD:

***** HHHHHHHH SSSSSSSS? *****

Welcome to DIALOG

Status: Connected

Dialog level 03.05.00D

Last logoff: 26dec03 12:07:37

Logon file001 29dec03 12:02:24

*** ANNOUNCEMENT ***

--File 654 - US published applications from March 15, 2001 to the present are now online. Please see HELP NEWS 654 for details.

--File 581 - The 2003 annual reload of Population Demographics is complete. Please see Help News581 for details.

--File 990 - NewsRoom now contains February 2003 to current records.
File 992 - NewsRoom 2003 archive has been newly created and contains records from January 2003. The oldest months's records roll out of File 990 and into File 992 on the first weekend of each month.
To search all 2003 records BEGIN 990, 992, or B NEWS2003, a new OneSearch category.

--Connect Time joins DialUnits as pricing options on Dialog.
See HELP CONNECT for information.

--SourceOne patents are now delivered to your email inbox as PDF replacing TIFF delivery. See HELP SOURCE1 for more information.

--Important news for public and academic libraries. See HELP LIBRARY for more information.

--Important Notice to Freelance Authors--
See HELP FREELANCE for more information

NEW FILES RELEASED

***DIOGENES: Adverse Drug Events Database (File 181)

***Emergency Room (File 454), Hospital Inpatient Profiles (File 462),
and Hospital Outpatient Profiles (File 463)

***World News Connection (File 985)

***Dialog NewsRoom - 2003 Archive (File 992)

***TRADEMARKSCAN-Czech Republic (File 680)

***TRADEMARKSCAN-Hungary (File 681)

***TRADEMARKSCAN-Poland (File 682)

UPDATING RESUMED

RELOADED

***Population Demographics -(File 581)

***CLAIMS Citation (Files 220-222)

REMOVED

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<
>>> of new databases, price changes, etc. <<<

KWIC is set to 50.

HIGHLIGHT set on as '*'

* * *

* * *

File 1:ERIC 1966-2003/Dec 24
(c) format only 2003 The Dialog Corporation

| Set | Items | Description |
|-----|-------|-------------|
|-----|-------|-------------|

| | | |
|-----|-------|-------|
| --- | ----- | ----- |
|-----|-------|-------|

Cost is in DialUnits

?b 155, 159, 5,73

29dec03 12:02:36 User259876 Session D579.1

\$0.31 0.088 DialUnits File1

\$0.31 Estimated cost File1

\$0.04 TELNET

\$0.35 Estimated cost this search

\$0.35 Estimated total session cost 0.088 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1966-2003/Dec W4

(c) format only 2003 The Dialog Corp.

***File 155: Medline is updating again (12-22-2003).**

Please see HELP NEWS 154, for details.

File 159:Cancerlit 1975-2002/Oct

(c) format only 2002 Dialog Corporation

***File 159: Cancerlit ceases updating with immediate effect.**

Please see HELP NEWS.

File 5:Biosis Previews(R) 1969-2003/Dec W3

(c) 2003 BIOSIS

File 73:EMBASE 1974-2003/Dec W3

(c) 2003 Elsevier Science B.V.

| Set | Items | Description |
|-----|-------|-------------|
|-----|-------|-------------|

| | | |
|-----|-------|-------|
| --- | ----- | ----- |
|-----|-------|-------|

?s (HSV (w) 1716) (s) (cancer or melanoma or tumor or tumour or neoplastic)

41764 HSV

562 1716

2348300 CANCER

198480 MELANOMA

2362888 TUMOR

280747 TUMOUR

633433 NEOPLASTIC

S1 29 (HSV (W) 1716) (S) (CANCER OR MELANOMA OR TUMOR OR TUMOUR
OR NEOPLASTIC)

?rd

...completed examining records

S2 10 RD (unique items)

?t s2/3,k/all

2/3,K/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

11875146 99316804 PMID: 10389942

Use of carrier cells to deliver a replication-selective herpes simplex
virus-1 mutant for the intraperitoneal therapy of epithelial ovarian
cancer.

Coukos G; Makrigiannakis A; Kang E H; Caparelli D; Benjamin I; Kaiser L R

; Rubin S C; Albelda S M; Molnar-Kimber K L
Department of Obstetrics and Gynecology, University of Pennsylvania
Medical Center, Philadelphia 19104, USA.

Clinical cancer research - an official journal of the American
Association for Cancer Research (UNITED STATES) Jun 1999, 5 (6)
p1523-37, ISSN 1078-0432 Journal Code: 9502500

Contract/Grant No.: PO-66726-S1; PHS

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Epithelial ovarian *cancer* (EOC) remains localized within the peritoneal cavity in a large number of patients, lending itself to i.p. approaches of therapy. In the present study...

... 1 (HSV-1) used as an oncolytic agent against EOC and the use of human teratocarcinoma PA-1 as carrier cells for i.p. therapy. *HSV*-1716*, a replication-competent attenuated strain lacking ICP34.5, caused a direct dose-dependent oncolytic effect on EOC cells in vitro. A single i.p. administration of 5×10^6 plaque-forming units resulted in a significant reduction of *tumor* volume and *tumor* spread and an increase in survival in a mouse xenograft model. PA-1 cells supported HSV replication in vitro and bound preferentially to human ovarian carcinoma surfaces compared with mesothelial surfaces in vitro and in vivo. In comparison with the administration of *HSV*-1716* alone, irradiated PA-1 cells, infected at two multiplicities of infection with *HSV*-1716* and injected i.p. at 5×10^6 cells/animal, led to a significant *tumor* reduction in the two models tested and the significant prolongation of mean survival in one model. Histological evaluation revealed extensive necrosis in *tumor* areas infected by *HSV*-1716*. Immunohistochemistry against HSV-1 revealed areas of viral infection within *tumor* nodules, which persisted for several weeks after treatment. Administration of HSV-infected PA-1 carrier cells resulted in larger areas of *tumor* infected by the virus. Our results indicate that replication-competent attenuated HSV-1 exerts a potent oncolytic effect on EOC, which may be further enhanced...

... the utilization of a delivery system with carrier cells, based on amplification of the viral load and possibly on preferential binding of carrier cells to *tumor* surfaces.

2/3,K/2 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

11185691 98062157 PMID: 9400985

Herpes simplex virus 1716, an ICP 34.5 null mutant, is unable to replicate in CV-1 cells due to a translational block that can be overcome by coinfection with SV40.

Randazzo B P; Tal-Singer R; Zabolotny J M; Kesari S; Fraser N W

The Wistar Institute, Philadelphia, PA 19104, USA.

Journal of general virology (ENGLAND) Dec 1997, 78 (Pt 12) p3333-9,
ISSN 0022-1317 Journal Code: 0077340

Contract/Grant No.: 1K08CA65839; CA; NCI; NS33768; NS; NINDS

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... mutants lacking the gene encoding infected cell protein (ICP) 34.5 exhibit an attenuated phenotype in models of pathogenesis and have been used for experimental *cancer* therapy. Recently it was shown that the HSV ICP 34.5 protein functions to prevent the host cell-induced double-stranded RNA-activated protein kinase (PKR)-dependent translational block that normally occurs during virus infection. We now report that an HSV ICP 34.5 mutant called *HSV*-1716* is unable to replicate in the simian kidney cell-derived line CV-1, due to a translational block. Moreover, we find

that this block can be overcome by simian virus 40 (SV40). This has been shown directly by infecting CV-1 cells with SV40 and *HSV*-1716* simultaneously, and indirectly via *HSV*-1716* infection of COS-1 cells (CV-1 cells transformed by an origin-defective mutant of SV40 that codes for wild-type T antigen). The translational...

2/3,K/3 (Item 3 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

10973065 97325813 PMID: 9182825

Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant.

Randazzo B P; Bhat M G; Kesari S; Fraser N W; Brown S M
The Wistar Institute, Department of Dermatology, University of Pennsylvania Medical System, Philadelphia 19104, USA.

Journal of investigative dermatology (UNITED STATES) Jun 1997, 108

(6) p933-7; ISSN 0022-202X Journal Code: 0426720

Contract/Grant No.: 1K08CA65839; CA; NCI

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Modified, non-neurovirulent herpes simplex viruses (HSV) have shown promise for the treatment of brain tumors, including intracranial *melanoma*. In this report, we show that *HSV*-1716*, an HSV-1 mutant lacking both copies of the gene coding-infected cell protein 34.5 (ICP 34.5), can effectively treat experimental subcutaneous human *melanoma* in mice. In vitro, *HSV*-1716* replicated in all 26 human *melanoma* cell lines tested, efficiently lysing the cells. Therapeutic infection of subcutaneous human *melanoma* nodules with *HSV*-1716* led to viral replication that was restricted to *tumor* cells by immunohistochemistry. Moreover, *HSV*-1716* treatment significantly inhibited progression of preformed subcutaneous human *melanoma* nodules in SCID mice and caused complete regression of some tumors. This work expands the potential scope of HSV-1-based *cancer* therapy.

2/3,K/4 (Item 4 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

09359524 21121343 PMID: 11229673

Intralesional injection of herpes simplex virus 1716 in metastatic melanoma.

Mackie R M; Stewart B; Brown S M

Lancet (England) Feb 17 2001, 357 (9255) p525-6, ISSN 0140-6736

Journal Code: 2985213R

Document type: Clinical Trial; Letter

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

We have previously shown that avirulent but replication-competent herpes simplex virus (*HSV*) 1716* causes cell death in human *melanoma* cell lines in vitro and selectively replicates in *melanoma* tissue in nude mice. We now present a pilot study of intratumoral injection of HSV1716 into subcutaneous nodules of metastatic *melanoma* in five patients with stage 4 *melanoma*. Two patients each received one injection, two received two injections, and one received four injections of 10(3) plaque-forming units HSV1716. In one patient, flattening of previously palpable *tumour* nodules was seen 21 days after two direct injections of HSV1716, and in injected nodules from all three patients who received two or more injections there was microscopic evidence of *tumour* necrosis. Immunohistochemical staining of injected nodules revealed evidence of virus

replication confined to *tumour* cells. These findings suggest that HSV1716 is non-toxic and could be of therapeutic benefit in patients with metastatic *melanoma*.

2/3,K/5 (Item 5 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

09171932 20476827 PMID: 11020355

Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model.

Lambright E S; Kang E H; Force S; Lanuti M; Caparrelli D; Kaiser L R; Albelda S M; Molnar-Kimber K L

Thoracic Oncology Research Laboratory, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA.

Molecular therapy - the journal of the American Society of Gene Therapy (UNITED STATES) Oct 2000, 2 (4) p387-93, ISSN 1525-0016

Journal Code: 100890581

Contract/Grant No.: P50-CA-83638; CA; NCI; P01-CA66726; CA; NCI; RO1-74958; PHS

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

HSV-*1716*, a replicating nonneurovirulent herpes simplex virus type 1, has shown efficacy in treating multiple types of human tumors in immunodeficient mice. Since the majority of the human population has been previously exposed to herpes simplex virus, the efficacy of HSV-based oncolytic therapy was investigated in an immunocompetent animal *tumor* model. EJ-6-2-Bam-6a, a *tumor* cell line derived from h-ras-transformed murine fibroblast, exhibit a diffuse growth pattern in the peritoneal cavity of BALB/c mice and replicate *HSV*-*1716* to titers observed in human tumors. An established intraperitoneal (ip) *tumor* model of EJ-6-2-Bam-6a in naive and HSV-immunized mice was used to evaluate the efficacy of single or multiple ip administrations of *HSV*-*1716* (4 x 10(6) pfu/treatment) or of carrier cells, which are irradiated, ex vivo virally infected EJ-6-2-Bam-6a cells that can...

...multiply treated, HSV-naive animals. Prior immunization of the mice with HSV did not significantly decrease the median survival of the single or multiply treated *HSV*-*1716* or the carrier cell-treated groups. These studies support the development of replication-selective herpes virus mutants for use in localized intraperitoneal malignancies.

2/3,K/6 (Item 6 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

08793424 20075752 PMID: 10609661

Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (*HSV*-*1716*) in human non-small cell lung *cancer*.

Toyoizumi T; Mick R; Abbas A E; Kang E H; Kaiser L R; Molnar-Kimber K L
Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.

Human gene therapy (UNITED STATES) Dec 10 1999, 10 (18) p3013-29, ISSN 1043-0342 Journal Code: 9008950

Contract/Grant No.: CA16520-24; CA; NCI; CA66727-S1; CA; NCI

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Combined therapy with chemotherapeutic agents and herpes simplex virus

type 1 ICP34.5 mutant (*HSV*-1716*) in human non-small cell lung *cancer*.

A replication-selective herpes simplex virus type 1 ICP34.5 mutant (*HSV*-1716*) has shown efficacy both in vitro and in vivo against human non-small cell lung *cancer* (NSCLC) cell lines but complete eradication of *tumor* has not been accomplished with a single viral treatment in our murine xenograft models. Therefore, strategies to enhance the efficacy of this treatment were investigated. We determined the oncolytic activity of *HSV*-1716* in NCI-H460 cells in combination with each of four chemotherapeutic agents: mitomycin C (MMC), cis-platinum II (cis-DDP), methotrexate (MTX), or doxorubicin (ADR). Isobologram analysis was performed to evaluate the interaction between the viral and chemotherapeutic agents. The oncolytic effect of *HSV*-1716* in combination with MMC was synergistic in two of five NSCLC cell lines. In the other three cell lines, the combined effect appeared additive. No...

... was observed. The in vivo effect of this combination was then examined in a murine xenograft model. NCI-H460 flank tumors were directly injected with *HSV*-1716* (4 x 10⁶ PFU) followed by intravenous MMC administration (0.17 mg/kg) 24 hr later. After 3 weeks, the mean *tumor* weight in the combined treatment group was significantly less than either individual treatment in an additive manner. The synergistic dose of MMC neither augmented nor inhibited viral replication in vitro and *HSV*-1716* infection did not upregulate DT-diaphorase, which is the primary enzyme responsible for MMC activation. In summary, the combination of *HSV*-1716* with common chemotherapeutic agents may augment the effect of HSV-based therapy in the treatment of NSCLC.

2/3,K/7 (Item 7 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

08768405 20049750 PMID: 10585055

Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system.

Lambright E S; Caparrelli D J; Abbas A E; Toyozumi T; Coukos G; Molnar-Kimber K L; Kaiser L R

Harrison Department of Surgical Research, University of Pennsylvania Medical Center, Philadelphia, USA.

Annals of thoracic surgery (UNITED STATES) Nov 1999, 68 (5) p1756-60; discussion 1761-2, ISSN 0003-4975 Journal Code: 15030100R

Contract/Grant No.: PO-66726-S1; PHS

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

BACKGROUND: Herpes simplex virus (*HSV*)-1716*, a replication-restricted herpes simplex virus type 1, has shown efficacy as an oncolytic treatment for central nervous system tumors, breast *cancer*, ovarian *cancer*, and malignant mesothelioma. We evaluated the efficacy of *HSV*-1716* in a murine lung *cancer* model, Lewis lung carcinoma. **METHODS:** Lewis lung carcinoma cells were infected with *HSV*-1716* and implanted in the flanks of mice at varying ratios of infected to uninfected cells. *Tumor* burden was assessed by measurement of the weight of the *tumor* nodule. The role of the immune system was examined by performing experiments in both immunocompetent and SCID mice. Tumors were implanted in the opposite flank to evaluate the vaccine effect. **RESULTS:** In immunocompetent and SCID animals, ratio of 1:10 (infected-to-uninfected) cells completely prevented *tumor* formation and ratio of 1:100 suppressed *tumor* growth. Established tumors at a distant site in the groups receiving *HSV*-1716* infected cells showed no difference in size versus control, suggesting absence of a vaccine effect. **CONCLUSIONS:** We conclude that *HSV*-1716* may provide a oncolytic therapy for lung *cancer* even in the absence of immune system induction and a "carrier" cell could potentially deliver this vector.

2/3,K/8 (Item 1 from file: 159)

DIALOG(R)File 159:Cancerlit

(c) format only 2002 Dialog Corporation. All rts. reserv.

02327237 97164668 PMID: 9012475

Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma.

Kucharczuk J C; Randazzo B; Chang M Y; Amin K M; Elshami A A; Sterman D H ; Rizk N P; Molnar-Kimber K L; Brown S M; MacLean A R; Litzky L A; Fraser N W; Albelda S M; Kaiser L R

Thoracic Oncology Research Laboratory, University of Pennsylvania Medical Center, Philadelphia 19104, USA.

Cancer Res (UNITED STATES) Feb 1 1997, 57 (3) p466-71, ISSN 0008-5472 Journal Code: 2984705R

Document Type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

...in the treatment of brain tumors. However, HSV-1 can infect and lyse a wide range of cell types. In this report, we show that *HSV*-1716*, a mutant lacking both copies of the gene coding ICP-34.5, can effectively treat a localized i.p. malignancy. Human malignant mesothelioma cells supported the growth of *HSV*-1716* and were efficiently lysed in vitro. i.p. injection of *HSV*-1716* into animals with established *tumor* nodules reduced *tumor* burden and significantly prolonged survival in an animal model of non-central nervous system-localized human malignancy without dissemination or persistence after i.p. injection...

2/3,K/9 (Item 2 from file: 159)

DIALOG(R)File 159:Cancerlit

(c) format only 2002 Dialog Corporation. All rts. reserv.

02322796 PMID: 97604982

Replication-restricted herpes simplex virus-based treatment of localized non CNS malignancy (Meeting abstract).

Kucharczuk; Randazzo; Elshami; Sterman; Rizk; Brown; Molnar-Kimber; Litzky; Fraser; Kaiser; Albelda

Thoracic Oncology Lab., Univ. of Pennsylvania Medical Center, Philadelphia, PA 19104

Proc Annu Meet Am Assoc Cancer Res 1996, 37, ISSN 0197-016X

Document Type: MEETING ABSTRACTS

Languages: ENGLISH

Main Citation Owner: NOTNLM

Record type: Completed

...brain tumors. However, HSV-1 can infect and lyse a wide range of other cell types. The purpose of this study was to determine if *HSV*-1716*, a mutant lacking both copies of the gamma-34.5 gene, could effectively treat localized intraperitoneal malignancy. Human malignant mesothelioma cells supported the growth of *HSV*-1716* and were rapidly lysed in vitro. Intraperitoneal injection of *HSV*-1716* into animals with established mesothelioma *tumor* nodules reduced *tumor* burden and significantly prolonged survival in an animal model of non-CNS localized human malignancy. Importantly, the *HSV*-1716* mutant was 'replication-restricted' to malignant cells, in that it did not disseminate or persist after intraperitoneal injection into SCID mice bearing human tumors. These...

... replication-restricted HSV mutant 1716 may be efficacious and safe for use in localized human malignancies of non-neuronal origin such as malignant mesothelioma, brain *cancer*, ovarian carcinoma, or bladder *cancer*.

2/3,K/10 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

0011875509 BIOSIS NO.: 199900135169

**Combination therapy with herpes simplex virus type 1 ICP34.5 mutant
(HSV-1716) and common chemotherapeutic agents for human non-small cell
lung *cancer* (NSCLC)**

AUTHOR: Toyozumi Takane (Reprint); Abbas Abbas E (Reprint); Caparrelli
David J (Reprint); Kang Eugene H (Reprint); Albelda Steven M; Kaiser
Larry R (Reprint); Molnar-Kimber Katherine L (Reprint)
AUTHOR ADDRESS: Dep. Surg., Univ. Pa. Sch. Med., Philadelphia, PA, USA**USA
JOURNAL: Cancer Gene Therapy 5 (6 CONF. SUPPL.): pS7-S8 Nov.-Dec., 1998
1998
MEDIUM: print
CONFERENCE/MEETING: Seventh International Conference on Gene Therapy of
Cancer San Diego, California, USA November 19-21, 1998; 19981119
ISSN: 0929-1903
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Citation
LANGUAGE: English

**Combination therapy with herpes simplex virus type 1 ICP34.5 mutant
(HSV-1716) and common chemotherapeutic agents for human non-small cell
lung *cancer* (NSCLC)**

?ds

| Set | Items | Description |
|---|----------|---|
| S1 | 29 | (HSV (W) 1716) (S) (CANCER OR MELANOMA OR TUMOR OR TUMOUR - OR NEOPLASTIC) |
| S2 | 10 | RD (unique items) |
| ?s (HSV (w) 1716) and (cancer or neoplastic or tumor or tumour) | | |
| | 41764 | HSV |
| | 562 | 1716 |
| | 34 | HSV(W)1716 |
| | 2348300 | CANCER |
| | 633433 | NEOPLASTIC |
| | 2362888 | TUMOR |
| | 280747 | TUMOUR |
| S3 | 31 | (HSV (W) 1716) AND (CANCER OR NEOPLASTIC OR TUMOR OR TUMOUR) |
| ?s s3 not py>1996 | | |
| | 31 | S3 |
| | 10724467 | PY>1996 |
| S4 | 1 | S3 NOT PY>1996 |
| ?t s4/3,k/all | | |

4/3,K/1 (Item 1 from file: 159)
DIALOG(R)File 159:Cancerlit
(c) format only 2002 Dialog Corporation. All rts. reserv.

02322796 PMID: 97604982

**Replication-restricted herpes simplex virus-based treatment of localized
non CNS malignancy (Meeting abstract).**

Kucharczuk; Randazzo; Elshami; Sterman; Rizk; Brown; Molnar-Kimber;
Litzky; Fraser; Kaiser; Albelda
Thoracic Oncology Lab., Univ. of Pennsylvania Medical Center,
Philadelphia, PA 19104
Proc Annu Meet Am Assoc Cancer Res 1996, 37, ISSN 0197-016X
Document Type: MEETING ABSTRACTS
Languages: ENGLISH
Main Citation Owner: NOTNLM
Record type: Completed

...brain tumors. However, HSV-1 can infect and lyse a wide range of other
cell types. The purpose of this study was to determine if *HSV*-1716*, a
mutant lacking both copies of the gamma-34.5 gene, could effectively treat